Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

HSCT may be best option for therapy-related ALL

Publish date:: June 24, 2020

Key clinical point: Therapy-related acute lymphoblastic leukemia may be a distinct clinical entity.

Major finding: Overall survival was longer for patients who underwent hematopoietic stem cell transplant.

Study details: A retrospective analysis of data on 59 patients with therapy-related acute lymphoblastic leukemia.

Disclosures: The authors did not disclose a funding source. Dr. Merchán and Dr. Aldoss reported no relevant disclosures.

Citation:

Merchán B et al. EHA25, Abstract EP391.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in ALL

In high-risk first relapse ALL, blinatumomab seen superior to consolidation chemo,

Well tolerated with promising responses in ALL/LL: Venetoclax plus navitoclax plus chemotherapy,

Highly effective in Ph-negative B-cell ALL: Hyper-CVAD with sequential blinatumomab,

COVID-19–related outcomes poor for patients with hematologic disease in ASH registry,

Study: Complications from childhood ALL and its treatment are common, but can be managed,